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Abstract
Background: Abdominal obesity and presence of the metabolic syndrome (MetS) significantly increase the risk of
developing diseases such as Type 2 diabetes mellitus (T2DM) with escalating emergence of MetS and T2DM
constituting a significant public health crisis worldwide. Lower prevalence of inflammatory and metabolic diseases such
as T2DM in countries with higher incidences of helminth infections suggested a potential role for these parasites in the
prevention and management of certain diseases. Recent studies confirmed the potential protective nature of helminth
infection against MetS and T2DM via immunomodulation or, potentially, alteration of the intestinal microbiota. This
Phase 1b safety and tolerability trial aims to assess the effect of inoculation with helminths on physical and metabolic
parameters, immune responses, and the microbiome in otherwise healthy women and men.
Methods: Participants eligible for inclusion are adults aged 18–50 with central obesity and a minimum of one
additional feature of MetS recruited from the local community with a recruitment target of 54. In a randomised,
double-blind, placebo-controlled design, three groups will receive either 20 or 40 stage three larvae of the human
hookworm Necator americanus or a placebo. Eligible participants will provide blood and faecal samples at their
baseline and 6-monthly assessment visits for a total of 24months with an optional extension to 36months. During
each scheduled visit, participants will also undergo a full physical examination and complete diet (PREDIMED), physical
activity, and patient health (PHQ-9) questionnaires. Outcome measurements include tolerability and safety of infection
with Necator americanus, changes in metabolic and immunological parameters, and changes in the composition of the
faecal microbiome.
Discussion: Rising cost of healthcare associated with obesity-induced metabolic diseases urgently calls for new
approaches in disease prevention. Findings from this trial will provide valuable information regarding the potential
mechanisms by which hookworms, potentially via alterations in the microbiota, may positively influence metabolic health.
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Background
Since 1980, numbers of obese or overweight adults and
children have grown exponentially worldwide to a current
estimate of 2.1 billion people, thus establishing obesity as
a pandemic and the fourth leading cause of death world-
wide in 2017 [1]. Specifically, abdominal obesity has been
highlighted as the central factor in metabolic syndrome
(MetS), a cluster of physiological, metabolic, and biochem-
ical risk factors including abdominal obesity, insulin resist-
ance, hypertension, and dyslipidaemia, as it appears to
precede all other factors [2]. Presence of MetS significantly
increases the risk of developing several life-threatening
diseases such as cancer, cardiovascular disease (CVD), and
Type 2 diabetes mellitus (T2DM) [2]. With almost one
quarter of the world’s population affected, the prevalence
of MetS in adults in rural Australia alone is 35.8%, and
numbers in the Asia-Pacific region are growing dispropor-
tionately [3], likely due to rapid socio-economic develop-
ment and adoption of the Western diet and sedentary
lifestyle [4]. Associated with MetS, the escalating emer-
gence of non-communicable diseases such as CVD and
T2DM constitutes a significant public health crisis for the
affected regions [3].
Central and visceral obesity observed in MetS are a
strong predictor for the development of T2DM, as they
promote chronic inflammation and subsequent insulin re-
sistance [5]. Worldwide numbers of patients with T2DM
are on the rise, and currently 8.8% of adults are living with
the disease, equating to 425 million people (http://www.
diabetesatlas.org). Although the causative mechanisms are
not exhaustively understood, chronic inflammation is
increasingly accepted as strongly implicated in the patho-
genesis of T2DM as excess calorie intake and sedentary
behaviour are in the development of obesity [6]. Vascular
dysfunction resulting from chronic inflammation en-
hances the risk of diabetic complications such as myocar-
dial infarction, peripheral arterial disease, and diabetic
nephropathy and retinopathy [7].
Interestingly, increasing incidence and prevalence of
inflammatory diseases such as T2DM, inflammatory bowel
disease, and asthma in developed countries offset the suc-
cessful reduction in parasite-related diseases following hel-
minth eradication efforts [8]. In 1989, the lower prevalence
of inflammatory diseases in transitioning or low-middle
income countries with higher incidences of helminth infec-
tions [9] led to development of the “Hygiene Hypothesis”
and generated suggestions of a potential role for symbiotic
parasites in the prevention and management of certain
inflammatory diseases [10]. Data from cross-sectional and
animal studies further corroborate this inverse relationship
between helminths and inflammatory diseases. A cross-
sectional study in Northern Australia unearthed an inverse
relationship between infection with Strongyloides stercoralis
and T2DM, indicating a possible protective relationship
[11]. A recent meta-analysis also confirmed a potential pro-
tective nature of helminth infection against T2DM [10]
with another study indicating an inverse relationship be-
tween helminth infection and CVD risk factors such as
dyslipidaemia [10]. Further supporting this notion, a recent
study in a helminth-endemic region of Indonesia showed
that anthelminthic drug treatment of people with an active
helminth infection significantly raised HOMA-IR values
and insulin resistance, suggesting that the removal of
worms was causally associated with worsened glycaemic
control [12]. Findings from animal studies confirm the sug-
gestion of a possible protective effect of helminth infections
against T2DM and MetS via processes of immunomodula-
tion [9], where helminth infections may dampen pro-
inflammatory immune responses and skew towards a type
2 immune response [9]. A further study also demonstrated
that infection with doses of 20 human hookworm Necator
americanus (Na) is safe, well tolerated, and associated with
Th2 and concomitant regulatory T cell responses [13, 14],
identifying Na as a potentially effective treatment for in-
flammation associated with MetS and T2DM. Additionally,
helminth infections may also modulate immune responses
indirectly via their effect on the composition of the intes-
tinal microbiota [15]. For example, infection of mice with
gastrointestinal helminths was able to prevent colonisation
with the pro-inflammatory bacterium Bacteroides vulgatus
by inducing a Th2 and regulatory immune response that
promoted the expansion of protective Clostridiales strains
[16]. Finally, a recent review of helminths and T2DM con-
cluded that chronic helminth infections influence the devel-
opment of metabolic diseases and that these effects can be
long lasting; however, human studies to date have been
cross-sectional and cannot infer causality [17]. The authors
called for controlled human helminth infection trials to
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better understand how these can modulate the immune
and metabolic response.
Herein we describe a randomised, double-blind, placebo-
controlled Phase 1b safety and tolerability trial that will as-
sess the effect of inoculation with 20 or 40 infective stage
three larvae (L3) of Na on body fat composition, inflamma-
tion and immune response, in otherwise healthy women
and men aged 18–50 with central obesity and features of
MetS over 24months (Table 1).
Hypotheses are that experimental infection with the
human hookworm Na
1. will be well-tolerated and safe in this cohort of
otherwise healthy but obese women and men.
2. will induce a biased Type 2 and regulatory immune
response with concomitant suppression of systemic,
pro-inflammatory Type 1 responses.
3. will stabilise or improve determinants of metabolic
disease.
4. will modify the composition of the gut microbiota.
Methods/design
Study design
Aims
The aims of this study are
1. to establish the acceptability, safety, and tolerability
of experimental infection with Na in obese women
and men with features of MetS
2. to conduct exploratory studies into the impact of
hookworms on stabilising or improving metabolic,
immune/inflammatory, and microbiological
parameters associated with metabolic disease
Design
This study is designed as a randomised, double-blind,
placebo-controlled Phase 1b safety and tolerability trial.
An initial recruitment target of 54 allows for a drop-out
rate of 20%, leaving 45 volunteers to participate in the
trial. Volunteers who meet the eligibility criteria, have
been approved following screening, and have given in-
formed consent (Additional file 1) will be randomised
into three trial groups. Groups 1 and 2 will be inoculated
with either 20 (2 × 10, n = 15) or 40 (2 × 20, n = 15) L3 of
Na with Group 3 (Placebo, n = 15) administered Tab-
asco® sauce in a solution identical in appearance to the
L3 solutions. All groups will be monitored over a period
of at least 24 months followed by an optional extension
to 36months to assess the impact of eliminating the
worm infection following anti-worm medication (Fig. 1).
Setting
Participants will be recruited from the Cairns and
Townsville regions in Far North Queensland, Australia.
As of June 2016, the regions' estimated populations were
162,000 (www.cairns.qld.gov.au Accessed 15 November
2018) and > 185,000, respectively (http://www.popula-
tion.net.au/townsville-population Accessed 3 December
2019). The study site is the James Cook University cam-
pus, located in Cairns and Townsville. The human hook-
worm Na is not endemic to these metropolitan areas.
Participant characteristics
Participant recruitment initiatives include advertising
in local media, notices around Cairns including the
James Cook University (JCU) Cairns campus, student
and staff email lists (with permission from the univer-
sity), and social media.
Inclusion criteria
Eligible for inclusion into this study are otherwise
healthy women and men in the primary age window for
progression to T2DM (18–50 years) [18] with central
obesity (waist circumference, WC > 90 cm for women
and > 102 cm for men) and increased insulin resistance
as assessed via abnormal homeostatic model assessment
of insulin resistance (HOMA-IR), i.e. HOMA-IR > 2.12
[19] or at least two other features of MetS: elevated
blood pressure (> 135/85 mmHg), dyslipidaemia (ele-
vated total cholesterol triglycerides, LDL or total choles-
terol/HDL ratio, low HDL), elevated fasting blood sugar
level, or abnormal liver function tests (abnormal alanine
transaminase, aspartate transaminase, alkaline phosphat-
ase, albumin and total protein, globulin, bilirubin, and
gamma-glutamyl transferase) suggesting fatty liver dis-
ease as per pathology report (Fig. 2, Additional file 2).
Volunteers must be willing to comply with all protocol
scheduled visits and provide written informed consent
prior to study entry with the option to withdraw at any
time. Women of child bearing potential should agree to
use acceptable methods of contraception.
Exclusion criteria
Exclusion criteria include pregnancy, established chronic
disease (CVD, diabetes, cancer, renal, gastrointestinal
disorders), history of substance abuse, current substance
abuse, major allergies, known immunodeficiency dis-
order, unstable asthma requiring significant maintenance
treatment, taking oral prescription medications or nutri-
tional supplements likely to interfere with study out-
comes, and inability to give informed consent (Fig. 2).
Processes, interventions, and comparisons
Initial clinical assessment and sample collection/week − 6
During the first visit, consenting participants will be
interviewed and examined by the trial doctor and eligi-
bility determined based upon inclusion criteria, medical
history, pre-existing conditions, current medications as
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well as recent travel to worm-endemic countries, known
previous worm infections, and deworming treatments.
The trial doctor will also conduct a full physical
examination during initial screening including height,
weight, examination of respiratory, cardiovascular and
nervous systems, and a pregnancy test for females.
Participants will be asked to attend Sullivan Nico-
laides Pathology (SNP) for a fasting blood test asses-
sing lipid profile, liver function, fasting glucose and
insulin (Table 2).
The study team will contact participants after the
screening visit to inform them of their eligibility to
proceed. If eligible, the study team will book the next
visit according to the study schedule. Clinical assess-
ments will consequently be completed during all follow-
up assessments to ensure patient safety and monitoring.
Pathology sampling (blood and faeces) will be repeated
Table 1 World Health Organisation Trial Registration Data Set
Data category Information
Primary registry and trial
identifying number
anzctr.org.au (ACTRN1261700818336)
Date of registration in
primary registry
05/06/2017
Secondary identifying numbers N/A
Source(s) of monetary
or material support
Far North Queensland Hospital
Foundation, Australian Institue
of Tropical Health and Medicine
Primary sponsor James Cook University
Secondary sponsor(s) None
Contact for public queries Prof Robyn McDermott
robyn.mcdermott@jcu.edu.au
Contact for scientific queries Prof Robyn McDermott, Australian
Institute of Tropical Health and
Medicine, Cairns, Australia
Public title Safety and tolerability of experimental
hookworm infection in humans with
metabolic disease
Scientific title Safety and tolerability of experimental
hookworm infection in humans with
metabolic disease: Proof of Concept
(Phase 1b) clinical trial
Countries of recruitment Australia
Health condition(s) or
problem(s) studied
Diabetes, Infection
Intervention(s) Active comparator: 20 or 40 larvae
of the human hookworm Necator
americanus (20 L3, 40 L3) over
24 months.
Placebo comparator: Tabasco
sauce solution
Key inclusion and
exclusion criteria
Ages eligible for study: 18–50 years;
Sexes eligible for study: both; Accepts
healthy volunteers: no
Inclusion criteria: Healthy adults
18–50 years, with central obesity
(WC > 90 cm for females and > 102 cm
for males) and increased insulin
resistance as assessed via abnormal
homeostatic model assessment of
insulin resistance (HOMA-IR), i.e.
HOMA-IR > 2.12 or at least two
other features of MetS: elevated
blood pressure > 135/85mmHg,
dyslipidaemia, or abnormal liver
function test suggesting fatty liver
disease. Have provided written
informed consent and are willing
to comply with all Protocol
scheduled visits. If of childbearing
potential, must be willing to use
the acceptable methods of
contraception.
Exclusion criteria: Pregnancy,
established chronic disease (CVD,
diabetes, cancer, renal, gut disorder),
history of substance abuse or current
substance abuse, major allergies,
known immunodeficiency disorder,
Table 1 World Health Organisation Trial Registration Data Set
(Continued)
Data category Information
asthma, taking prescribed medications
or nutritional supplements likely
to interfere with study outcomes,
inability to provide informed
consent.
Study type Interventional
Allocation: block randomised;
intervention model: parallel
assignment; Masking: double-blind,
sealed envelopes and containers
Primary purpose: prevention
Phase 1
Date of first enrolment March 2018
Target sample size 45
Recruitment status Recruiting
Primary outcome(s) Safety of experimental inoculation
with 20 L3, defined by (a) Number
of reported adverse events (AEs),
relative to placebo cohort, (b)
Assessment of general health
and (c) Successful completion of
24-month trial. Adverse reactions:
including but not limited to
abdominal pain, rash, fever, weight
loss, fatigue, nausea (mild, moderate
or severe as assessed by trial doctor).
Key secondary outcome(s) Changes in insulin sensitivity from
blood pathology taken at each
participant contact point during
the 24-month trial; Change in BMI
measured by any alteration in
weight (kg) and height (cm); Change
in waist circumference (cm) Change
in bacterial richness of microbiome
measure by shotgun assay of faecal
sample
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at intervals throughout follow-up. The schedule of visit
requirements is detailed below.
Baseline visit/week − 4
During this visit, the study doctor will review the labora-
tory test results, confirm continued eligibility for participa-
tion, perform a full physical examination, and administer
diet, health and activity questionnaires, which have been
previously validated [20–23]. Blood and faecal samples will
be collected and body composition determined via dual-
energy X-ray absorptiometry (DEXA) (Table 1). The study
doctor will obtain written informed consent for storage of
health information and/or blood or tissue samples in the
university’s Biobank.
Treatment period/week 0 to week 104
The treatment period will last up to 104 weeks during
which participants will be required to attend the clinic for
two inoculation visits eight weeks apart and four evalu-
ation visits approximately 26 weeks apart. Participants
may also have telephone and/or Skype appointments with
a designated study team member to monitor their health
status and promote retention; these visits will be sched-
uled with participants by negotiation. At the end of the
treatment period, participants will have their final blood
and stool tests and DEXA scan, complete the scheduled
questionnaires, and undertake an exit consultation and
examination with the study doctor. Furthermore, as a
mandatory requirement of the study, participants will be
provided with the anthelmintic treatment mebendazole
(100mg to be taken twice daily for 3 days to clear the
hookworm infection) at no cost to them; however, it is not
mandatory for participants to take this medication. Partic-
ipants electing to refrain from taking the anthelmintic
treatment (that is choosing to keep their helminths) fol-
lowing completion of the 104-week period will be advised
that their future medical care will be passed onto their
general practitioner. At 104 weeks, the study will become
unblinded, and there will be an optional 52-week exten-
sion to the study for willing participants to examine the
impact of de-worming medication on safety, immuno-
logical and metabolic parameters.
Randomisation and inoculation (week 0 and week 8)
Previous studies have established the safety of experi-
mental inoculation with Na in dose-controlled condi-
tions [14, 24] and indicate that Na is well tolerated in
human trial subjects, up to a dose of 25 third stage
Fig. 1 Trial design flowchart
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larvae (L3), beyond which adverse effects such as ab-
dominal pain become more problematic [25]. Doses as
high as 50 L3 have been associated with abdominal pain,
nausea and oedema [26]; therefore, doses of 20 and 40
L3 have been selected for the current study and are con-
sistent with doses from a parallel study in people with
coeliac disease (Trial identifier NCT02754609). The allo-
cation sequence for the three cohorts was generated by
random block number generation (block size of 6). The
unblinded researcher will subsequently implement allo-
cation using sequentially numbered, opaque, sealed en-
velopes and containers. The inoculum, either 10 x L3, 20
x L3 or Tabasco (placebo) will be prepared by the un-
blinded research assistant freshly on site following an
established protocol that has been used for similar previ-
ous studies [14]. Larvae are decontaminated using iodine
disinfectant and individually selected by an experienced
researcher based on morphological integrity and active
motility, so we can be certain that larval viability is opti-
mal. All inocula will appear identical, and study doctor,
investigators, participants, and data analysts will be
blinded. Consenting participants, depending on rando-
mised group allocation, will be inoculated with Na
larvae, either 10 x L3 or 20 x L3 in 300 μL of de-ionised
water. Two doses will be administered 8 weeks apart
(Table 2) by applying the solution to a dressing pad,
which will be placed on the participant’s forearm. Partic-
ipants will be advised that there may be localised itch
and irritation at the inoculation site, much the same as
would be experienced if chilli pepper were to be rubbed
into the skin. Following inoculation, participants will
be observed for one hour in case of an adverse re-
sponse. One medical monitor will remain un-blinded
for the study duration. Unblinding of participants
may occur upon advice from the safety management
committee in case of a serious adverse effect (SAE).
Participants will be instructed of the importance of
maintaining their normal hygiene practices (using a
toilet) during the study. This is essential for prevent-
ing parasite eggs that are shed in the faeces from
developing in the environment into the infective stage
larvae, a process that takes 7–10 days.
Safety and clinical monitoring During the initial
screening visit and every visit thereafter (or as required
in the event of an adverse event), general health assess-
ments, physical examination and vital signs (blood pres-
sure, heart rate, temperature and respiratory rate) will be
obtained to ensure safety and monitoring. Urine preg-
nancy test will be performed for female participants at
the beginning of the study (positive tests exclude the
participant from the trial) and urinary beta human
chorionic gonadotropin testing will be performed during
the study, if pregnancy is suspected. Should pregnancy
occur during the study, the participant will be treated as
an Early Termination.
Incidence and severity of adverse events (AEs) and
SAEs will be evaluated formally via structured question-
naires (Additional file 3) reviewed by the investigating
clinician and informally via participant-initiated contact.
The most significant side effects are likely to occur dur-
ing the first 4–6 weeks following inoculation as the
worms anchor themselves to the intestinal mucosa to fa-
cilitate feeding and avoid ejection by gut peristalsis [27].
Common side effects during this initial colonisation in-
clude abdominal pain, increased flatulence, nausea, and
bloating [28]. The second inoculation visit eight weeks
after the first inoculation will provide an ideal opportun-
ity to identify/monitor any side effects. Potential side
effects have also been outlined in an extensive partici-
pant information sheet provided prior to informed con-
sent and are reiterated during the first inoculation visit.
Participants are encouraged during the first inoculation
visit to contact the trial doctor should they notice any
unusual signs and symptoms. If deemed necessary by
the trial doctor, participants will be called in for an
Fig. 2 Flow diagram of inclusion/exclusion criteria. WC, waist
circumference; CVD, cardiovascular disease; GI, gastro-intestinal;
HOMA-IR, homeostatic model assessment of insulin resistance; MetS,
metabolic syndrome; BP, blood pressure; BSL, blood sugar level
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additional examination, during which they can elect to
discontinue with the trial. Should the symptoms be
consistent with potential side effects of hookworm infec-
tion, the participant may become unblinded and offered
anthelmintic medication.
Pathology samples (blood) will be monitored every
6 months for incidence and severity of laboratory ab-
normalities (Table 2). In the event of a SAE related
to the trial, the participant will firstly be referred to
their own GP and the case referred to an independent
safety committee. With the consent of the participant,
their regular GP will be notified routinely of their
participation in the study at commencement. This will
be in the form of a letter stating the nature of the
study, objectives, and concomitant drugs to be
avoided; the participant will also receive a copy of
this letter.
Outcomes
The primary outcome measure will be the safety of
experimental hookworm infection of otherwise healthy
women and men with 20 Na L3 as evaluated by num-
ber of reported AEs and SAEs, assessment of general
health, and successful completion of the 24-month
trial.
Secondary outcomes include:
1. safety/tolerability of the higher dose of 40 Na L3
2. longitudinal and inter-cohort changes in
metabolic parameters (HOMA-IR, DEXA, WC,
body mass index, fasting insulin and glucose,
lipopolysaccharide-binding protein, glycated
haemoglobin, blood pressure, resting heart rate,
C-reactive protein, adiponectin, full blood count,
white blood cell count, omega-3 poly-
Table 2 Schedule of investigations
BP, blood pressure; HR, heart rate; Temp, temperature; Resp, respiratory rate; HIV, human immunodeficiency virus; HepB & C, hepatitis B and hepatitis C; FBC, full
blood count; U & E, urea and electrolytes; CRP, C-reactive protein; PUFA, polyunsaturated fatty acids; Hb1Ac, glycated haemoglobin; LPSBP, lipopolysaccharide-
binding protein; UACR, urinary albumin-creatinine ratio; DEXA, dual-energy X-ray absorptiometry; PBMC, peripheral blood mononuclear cells
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unsaturated fatty acid profile, urinary albumin-
creatinine ratio)
3. immunological parameters (fluctuations in blood
and serum Type 1 and Type 2 immune responses)
4. longitudinal and inter-cohort changes in the
composition of the faecal microbiome
5. impact of de-worming medication on, safety,
immunological and metabolic markers
Data collection, management, and statistical analyses
All eligible participants will be assigned a unique identi-
fication number at their first screening visit. Participant
confidential data, including anthropometric measures,
lifestyle, and medical history, will be recorded on a hard-
copy Case Report Form (Additional file 4), which will
then be entered into a password protected electronic
database developed specifically for this trial. Hard copy
Case Report Forms will be stored in participant trial
folders in a locked cabinet in a secure environment at
the JCU Cairns campus. Access to the folder containing
the databases will be restricted to study personnel only,
who will have signed a confidentiality agreement as a
condition of their involvement in the study. Data from
the final trial data set will be provided to investigators
and statisticians in de-identified electronic format and
this data will be linked to Case Report Form data using
the unique identification number, initials, and date of
collection. While a data management team was not
formed due to minimal risks associated with the study,
data will be audited regularly by independent monitors
for independent source data verification.
At trial conclusion, each participant will be provided
with an individual report including their baseline test re-
sults and any changes over the study period. At this
time, they will also be informed of study allocation
(20 x L3, 40 x L3, placebo). Upon publication of results,
the participants can opt to receive a copy of the
manuscript.
Sample size
This Phase 1b safety and dose-ranging study will include
45 participants with 15 to be infected with 20 x L3, 15
to be infected with 40 x L3, and 15 in the placebo con-
trol group. In the absence of other effect size data from
human trials upon which to base a power calculation,
and as a change in HOMA-IR from Baseline is a primary
metabolic outcome of this study, we have adapted the
SUGARSPIN HOMA-IR result [29] and assume an effect
size of 1.06 over 2 years. A total of 15 participants in
each group reflects 80% power to detect an effect size of
1.06 using the T-statistic and 1.023 using Z-statistic.
The aim to recruit 54 participants allows for a potential
drop-out rate of 20%.
Data processing and statistical analyses
Safety of infection The primary outcome, the safety of
infection with 20 Na L3, will be assessed using a chi-
squared test of proportions to determine any differences
in the proportions satisfying the safety criteria at 24
months between the placebo, 20 x L3 and 40 x L3
groups. Kaplan Meir models will be used to assess pro-
gression throughout the study, and Cox regression
models will assess safe progression through the study.
Standard descriptive statistics will be performed on all
outcome measures at Baseline, all interim points of as-
sessment, and at 24 months after inoculation (categorical
variables: absolute and relative frequencies; numerical
variables: mean and standard deviation or median and
interquartile range, dependent on data distribution).
Successful Na infection will be confirmed using qPCR
detection of parasite eggs in faecal samples taken at
Week 26. The faecal sample collected at Baseline (Week
-4) will be used for assessment of current or previous
helminth infections that could have interfered with trial
outcomes.
Metabolic parameters Changes in metabolic determi-
nants, in particular changes in body mass, visceral fat
mass (DEXA), insulin sensitivity (HOMA-IR), and adipo-
nectin will be analysed via comparison of Baseline and
follow-up data and visually checking the outcome mea-
sures moved in the expected direction for each alloca-
tion group. Paired statistical analysis (Chi-square and t-
tests) may be conducted between intervention and con-
trol groups, if the sample size warrants.
Impact of helminth infection on immune status
Serum samples collected at each scheduled visit will be
batch-analysed using a custom-panel of 17 cytokines
(IFNγ, IL-1β, IL-12p70, IL-2, IL-4, IL-6, TNF, IL-10, IL-
17A, IL-12p40, IL-5, IL-13, IL-15, IL-18, IL-33, MCP-1,
MIP-1α) for circulating inflammatory biomarkers associ-
ated with metabolic disease using cytometric bead array.
Mean cytokine levels in placebo and hookworm groups
will be compared by general linear models. Peripheral
blood mononuclear cells will be processed at scheduled
visits and analysed using flow cytometry for expression
of markers of cell phenotype (CD3, CD19, CD4, CD8),
activation (CD27, CD45RA, CD45RO, CD69) and func-
tion (CD25, CRTH2, CTLA4, FOXP3, IL-2, IL-4, IL-5,
IL-10, IL-17A, IFNγ and TNF).
Impact of helminth infection on faecal microbiota
Faecal specimens collected in anaerobic sample collec-
tion containers will be stored at − 80 °C and, later, DNA
will be extracted prior to genome-wide shotgun sequen-
cing to describe the composition and metabolic potential
of the microbiota. Following quality filtering, the QIIME
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pipeline will be used for operational taxonomic unit
(OTU) analysis and Beta diversity will be analysed using
UniFrac. Longitudinal comparisons will be made be-
tween Baseline, 12 and 24months looking at diversity
and any changes in OTUs between treatment and pla-
cebo groups. These data, along with clinical and im-
munological data, will be analysed subsequently in an
integrative fashion to more comprehensively define the
biological impact of experimental Na infection on indi-
viduals with metabolic disease.
Missing data and early termination Two research
team members will review data from each participant to
identify and address missing information. To account for
missing data at the analysis stage, this study will follow
the method prescribed in Jakobsen et al. [30]. Specific-
ally, complete case analysis will be used as the primary
analysis if the proportion of missing data is considered
negligible (i.e. < 5%) and the number of participants lost
to follow up is comparable across study groups. Multiple
imputation will be trialled during analysis should miss-
ing data exceed 5%, is spread across both independent
and dependent variables, and is likely missing at random.
Should missing data exceed 40%, no imputation will be
undertaken and results will be interpreted in the context
of this limitation [30]. Early termination and withdrawals
from the trial will be recorded throughout the interven-
tion and evaluation periods.
Discussion
To our knowledge, this is the first study to examine the
long-term safety/tolerability of experimental inoculation
with different doses of the hookworm Na in human sub-
jects with central adiposity and signs of MetS. With
safety of helminth therapy as the primary outcome, this
study will also allow observation and quantification of
the longer-term effects of helminth therapy on metabolic
disease progression, providing a foundation for future
research into dose-controlled helminth-based therapies.
The steeply rising cost of healthcare associated with
overweight and obesity-induced metabolic diseases, in-
cluding T2DM, in Australia [31] and increasing cases of
obesity and T2DM in children of obese or overweight
mothers [32] urgently calls for new approaches in pre-
venting disease progression. Several compelling lines of
evidence from animal models and human studies point
to a potential role for helminths in significantly reducing
the impact of obesity on disease progression. Pathways
may involve skewing the immune response to a Th2 or
regulatory (anti-inflammatory) response as well as alter-
ation of the gut microbiota with helminth infection. We
are pioneering the safe delivery of experimental Na in-
fection in human trials and are, thus, uniquely placed to
undertake a world-first proof-of-principle trial to
determine the safety and effectiveness of Na infection in
limiting the inflammatory and metabolic cascades that
are associated with obesity and T2DM.
Recent research has highlighted the complex interplay
between the organisms that comprise our intestinal
microbiota (commensal bacteria), macrobiota (helminths),
and the host mucosal immune response. Consequently,
the absence of either micro- or macrobiota may disturb
homeostasis in the host and predispose the immune sys-
tem to a more pro-inflammatory response [33]. Helminths
can directly influence the immune regulatory function via
secretion of various products and indirectly via alteration
of the microbiota [33]. In turn, alteration of the micro-
biota can also promote or depress helminth presence in
the host [33]. Critically, these interactions are fundamental
in shaping the health and homeostasis of the immune sys-
tem; however, the mechanisms involved remain poorly
understood. The present trial will offer a rare opportunity
to examine the nature, kinetics, and interactions of
parasite-induced changes in systemic immune responses,
in composition of the gut microbiota, and in metabolic
status within the carefully controlled context of a hook-
worm challenge trial. The findings will provide valuable
information regarding the potential mechanisms by which
hookworms, potentially via alterations in the microbiota,
may positively influence metabolic health.
While live worm therapy is unlikely to be a widely ac-
ceptable therapy in T2DM prevention for the general
public, discovering novel immune-regulatory, worm-
secreted molecules may attract investment from pharma
for other inflammatory conditions. Hence, this trial will
be fundamental for providing the rationale for future
endeavours to identify hookworm-secreted factors that
could be tested as therapeutics that are more amenable
to wider populations and have commercial potential.
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